Genocea Biosciences (NASDAQ:GNCAQ) vs. Protalix BioTherapeutics (NYSE:PLX) Financial Comparison

Genocea Biosciences (NASDAQ:GNCAQ) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership.

Profitability

This table compares Genocea Biosciences and Protalix BioTherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	N/A	N/A
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Analyst Ratings

This is a summary of current ratings for Genocea Biosciences and Protalix BioTherapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genocea Biosciences	0	0	0	0	0.00
Protalix BioTherapeutics	0	0	1	0	3.00

Protalix BioTherapeutics has a consensus price target of $12.00, suggesting a potential upside of 483.94%. Given Protalix BioTherapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Genocea Biosciences.

Institutional and Insider Ownership

16.5% of Protalix BioTherapeutics shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Genocea Biosciences and Protalix BioTherapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A
Protalix BioTherapeutics	$76.38 million	2.17	$8.31 million	$0.18	11.42

Protalix BioTherapeutics has higher revenue and earnings than Genocea Biosciences.

Risk & Volatility

Genocea Biosciences has a beta of 2.53, suggesting that its stock price is 153% more volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of -0.01, suggesting that its stock price is 101% less volatile than the S&P 500.

Summary

Protalix BioTherapeutics beats Genocea Biosciences on 6 of the 11 factors compared between the two stocks.

About Genocea Biosciences

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts. The plan was later approved as Chapter 11 liquidation on May 11, 2023.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.